ZZPZH(SH:600436) Shang Hai Zheng Quan Bao·2025-10-17 19:49Core Viewpoint - The company has announced the completion of the first subject enrollment in the Phase III clinical trial of its innovative traditional Chinese medicine, Wen Dan Pian, which aims to treat mild to moderate generalized anxiety disorder. This development is not expected to have a significant impact on the company's financial status and operating performance for the current year [9][12]. Financial Data - The company has reported that the cumulative research and development investment for Wen Dan Pian is approximately 55 million yuan [11]. - The financial data for the first three quarters of 2025 has been disclosed, but specific figures are not provided in the available documents [15]. Clinical Trial Information - Wen Dan Pian is classified as a Class 1 innovative traditional Chinese medicine and is designed to treat mild to moderate generalized anxiety disorder [9][10]. - The Phase III clinical trial is a multi-center, randomized, double-blind, placebo-controlled study, with the primary efficacy indicator being the reduction in HAMA score from baseline at week 12 [10]. Market Context - The global prevalence of anxiety disorders is reported to be 4.4%, with a lifetime prevalence of 7.6% and an annual prevalence of 5.0% in China [12]. - The sales scale of anti-anxiety medications in Chinese hospitals reached 2.444 billion yuan in 2024 [12].